AstraZenecas Tagrisso Significantly Improved Overall Survival in the Phase 3 Trial for FirstLine EGFRMutated NSCLC

AstraZeneca’s Tagrisso Significantly Improved Overall Survival in the Phase 3 Trial for First-Line EGFR-Mutated NSCLC

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations. TAGRISSO showed a statistically-significant and clinically-meaningful improvement in OS, a secondary endpoint in …

More From BioPortfolio on "AstraZeneca’s Tagrisso Significantly Improved Overall Survival in the Phase 3 Trial for First-Line EGFR-Mutated NSCLC"